Prescient Therapeutics (PTX) is a clinical stage oncology company developing novel compounds that show great promise as potential new therapies to treat a range of solid and hematological cancers.
The Company’s novel compounds inhibit key tumor survival pathways, inhibiting cancer growth and overcoming resistance to prior therapies.
Three Additional US Patents Granted
ROTH Conference Presentation
PTX presentation for 29th Annual ROTH Conference
First Cohort Successfully Completed in Phase 1b/2 AML Trial
PTX to present at 29th Annual Roth Conference
Appendix 4D and Half Year Financial Report